J&J Delivers No Evidence FDA Knew Of "Phantom" Recall - Congressional Staff
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson failed to provide proof that FDA acknowledged the firm's plan for a "phantom" recall of a Motrin product, according to Capitol Hill staff
You may also be interested in...
J&J Directors Find Root Causes But Little Blame For OTC Quality Issues
A report by a Johnson & Johnson special committee finds organizational and middle management changes at the firm were the root causes of manufacturing and quality control lapses in the OTC drug business.
Issa Scolds FDA On Failure To Inspect McNeil Plant
A key House committee chairman questions why FDA has not inspected McNeil Consumer Healthcare's Puerto Rico plant despite a requirement that the Johnson & Johnson business pay the agency's costs.
FDA Enforces Consent Decree Over J&J/McNeil's OTC Manufacturing
FDA will wield tight oversight of Johnson & Johnson subsidiary McNeil Consumer Healthcare's OTC manufacturing operations under a consent decree filed after the firm's quality-control changes failed to satisfy the agency.